Skip to content

EFFECT OF THE HOMOEOPATHIC MEDICINES IN ACUTE PAIN

A RANDOMIZED CONTROLLED TRIAL TO ASSESS THE EFFECTIVENESS OF INDIVIDUALIZED HOMOEOPATHIC MEDICINES IN ACUTE PAIN - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/066301
Enrollment
100
Registered
2024-04-25
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R52- Pain, unspecified

Interventions

Intervention1: Homoeopathy: Individualized Homoeopathic Drugs Dose: 50th Millesimal potencies / Centesimal Potencies Frequency of Dosing: 2 Hourly / 3 Hourly / 4 Hourly / QID / TDS Route of Administ

Sponsors

Tantia University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All the patients presenting with acute pain. 2. Patients of all age group and both sexes. 3. Patients taking a prescription medication (NSAIDs, acetaminophen, and aspirin) episodically (or as needed) for the management of pain, agrees to discontinue its use prior to or at the Screening and Baseline Visit 4. Patients agreeing to not commence any new prescription medication for the management of pain throughout the study 5. Patients agreeing to not commence any injection therapy for pain during the course of the study 6. Patients agreeing to not use acupuncture, biofeedback, or transcutaneous electrical nerve stimulation (TENS) for the management of pain during the course of the study.

Exclusion criteria

Exclusion criteria: 1. Terminally ill patients. [eg. congestive heart failure, renal failure or dialysis etc.] 2. Patients unwilling to give the consent. 3. Patients with pre-existing opiate therapy; and patients with dependencies on tobacco, alcohol, opioids, or other substances. 4. Patients with angina, bronchospasm, bronchial asthma, bronchospasm (chronic obstructive pulmonary disease and emphysema), diabetes mellitus, hyperthyroidism, fibromyalgia, or uncontrolled seizures or known hypersensitivity. 5. Anything that, in the opinion of the investigator, would place the participant at increased risk or preclude the participantââ?¬•s full compliance with or completion of the study

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale (VAS) measuring pain intensityTimepoint: Visual Analogue Scale (VAS) at Baseline And After 1 week of intervention

Secondary

MeasureTime frame
Health-related quality of life (HRQOL)Timepoint: Health-related quality of life (HRQOL) at Baseline & after 1 week of intervention

Countries

India

Contacts

Public ContactADITI CHADHA

Sri Ganganagar Homoeopathic Medical College Hospital and Research Institute

drsunilbishnoi84@gmail.com9460631101

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026